Business, energy, technology, markets and global industry news from Business News Today

zanidatamab

PharmaDeviceNews zanidatamab
Pharma & Biotech

Ziihera extends overall survival versus trastuzumab in Phase 3 first-line HER2-positive gastroesophageal cancer trial

Jazz Pharmaceuticals says a second interim analysis of HERIZON-GEA-01 found statistically significant and clinically meaningful overall survival improvement with Ziihera plus chemotherapy versus trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.

Read More
Pharma & Biotech

Jazz wins first-line Ziihera approval as HERIZON-GEA-01 resets the HER2 treatment benchmark

FDA has approved two Ziihera-based first-line regimens in HER2-positive advanced gastroesophageal adenocarcinoma after the Tevimbra combination improved median overall survival from 19.2 to 26.4 months.

Read More
Representative image of a cancer care specialist reviewing gastroesophageal scan data as BeOne Medicines’ HER2-positive gastroesophageal cancer results draw attention after ASCO 2026.
Pharma & Biotech

Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?

Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.

Read More
Representative image: ALX Oncology’s evorpacept update highlights how CD47-high biomarker data and HER2-positive metastatic breast cancer trial design could shape the next phase of oncology drug development.
Pharma & Biotech

Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study

ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.

Read More